YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors
Authors' conclusion
YAP1 is a potential novel prognostic marker in patients with ACC. Its deregulation contributes to adrenocortical tumorigenesis partially through crosstalk between Hippo/YAP1 and Wnt/β-catenin pathways. YAP1 inhibition is a new antitumor target.
Study context
- Population
- Pediatric and adult cohorts with adrenocortical cancer (ACC); adrenocortical cell line; murine xenograft model of ACC
Methodological detailspediatric and adult cohorts, in vitro adrenocortical cell line, murine xenograft model
- Pediatric and adult cohorts
- In vitro adrenocortical cell line
- Murine xenograft model
Main finding
As reported in the abstract
- High YAP1 expression was associated with lower survival in all cohorts
- YAP1 methylation signature was associated with patients' prognosis
- YAP1 inhibition reduced ACC cell viability through cell cycle arrest in G0/G1, and inhibited epithelial-mesenchymal transition and cell invasion
- YAP1 modulated β-catenin protein levels and transcription activity; β-catenin partially mediated the effect of YAP1 on adrenocortical tumorigenesis
- In vivo, verteporfin impaired tumor growth and Ki67 immunoreactivity in xenografts
Original publication
YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors. J Clin Endocrinol Metab. Published 10 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →